MedTrace Logo

Selenium in Mild Thyroid Eye Disease in North America

NCT02112643 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-08-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether sodium selenite is helpful in the treatment of mild thyroid eye disease in North America.

Conditions

  • Thyroid Associated Ophthalmopathies

Interventions

DRUG

Sodium selenate

A 100 microgram pill will be orally administered twice a day for 6 months.

DIETARY_SUPPLEMENT

Sugar pill

The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.

Sponsors & Collaborators

  • International Thyroid Eye Disease Society

    collaborator UNKNOWN

  • Columbia University

    lead OTHER

Principal Investigators

  • Micahel Kazim, MD · International Thyroid Eye Disease Society

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-11-16
Completion
2016-11-16
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02112643 on ClinicalTrials.gov